- Home
- UTC Development
- Antibody-Antibiotic Conjugate (AAC) Development
- Bacterial Infection related Antibody Discovery
- Staphylococcus aureus related Antibody Discovery
- Anti-IsdB Antibody Discovery
Anti-IsdB Antibody Discovery Service
As a leading company that provides antibody services, Creative Biolabs is committed to offering integrated antibody discovery and development services for clients all over the world. Creative Biolabs now provides antibody customization services for Staphylococcus aureus (S. aureus) iron-regulated surface determinant B (IsdB) by advanced platforms to help your projects. Our professional scientist team has extensive experience in antibody development and engineering, and we are capable of providing customized service to meet every client's specific demands.
IsdB Introduction
S.aureus is a human pathogen that causes invasive and recurring infections, including endocarditis, osteomyelitis, and skin and soft tissue infections. IsdB is a conserved protein expressed on the cell surface of S. aureus in iron limited environments, with an molecular weight (MW) of approximately 72 kDa. The protein is up-regulated under iron-restricted conditions and functions to capture and import heme iron from hemoglobin. IsdB also promotes bacterial invasion into human cells.
Fig.1 IsdB is exposed on the cell surface.1,2
Protein Structure
Free iron is not available in most environments, so organisms need high-affinity systems to acquire iron. S.aureus employs the iron-responsive surface determinant (Isd) system as its primary heme-iron uptake pathway. IsdB and IsdH are anchored to the cell wall by a mechanism requiring a C-terminal sorting signal. Hemoglobin or hemoglobin-hemoglobin complexes are bound by Near iron-Transport (NEAT) domains within IsdB or IsdH. Heme is stripped from the host proteins and transferred between NEAT domains through IsdA and IsdC to the membrane transporter IsdE and IsdF for internalization. Once internalized, heme can be degraded by IsdG or IsdI, thus liberating iron for the organism.
Antibody-based Therapy
As reported, monoclonal antibodies (mAbs) against IsdB have opsonophagocytic killing activity and observably enhanced survival in the murine sepsis model in Balb/c mice. Antibodies against IsdB are thought to block heme-iron scavenging during infection. Besides, IsdB can induce human protective CD4(+) T-cell immune response. IsdB is currently being investigated for clinical efficacy against S. aureus infection, and the activity of IsdB specific antibody supplements the growing body of evidence to support targeting this antigen for therapy development.
Considering the prevalence of drug-resistant bacteria, a possible strategy to improve the current situation is to combine an approach designed to enhance the host immune response with antibiotic therapy against the drug-resistance pathogen. Accordingly, Antibody-antibiotic conjugate( AAC) has the advantages of both antibiotic and anti-bacteria mAbs, which could expand the therapeutic options, reduce the duration of therapy. With the novel technology platform and professional antibody experts, Creative Biolabs is capable of providing you with the best antibody development services to help your AAC project. If you are interested in the anti-IsdB antibody development services that we provide, please feel free to contact us for more details.
References
- Schneewind, Olaf, and Dominique M. Missiakas. "Protein secretion and surface display in Gram-positive bacteria." Philosophical Transactions of the Royal Society B: Biological Sciences 367.1592 (2012): 1123-1139.
- Distributed under Open Access License CC BY 4.0, without modification.
For Research Use Only. NOT FOR CLINICAL USE.
Online Inquiry
Welcome! For price inquiries, please feel free to contact us through the form on the left side. We will get back to you as soon as possible.